Latest Insider Transactions at Protagonist Therapeutics, Inc (PTGX)
This section provides a real-time view of insider transactions for Protagonist Therapeutics, Inc (PTGX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Protagonist Therapeutics, Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Protagonist Therapeutics, Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2022
|
Arturo Md Molina Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+50.0%
|
-
|
|
Aug 23
2022
|
Dinesh V Ph D Patel President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.2%
|
$80,000
$4.21 P/Share
|
|
May 04
2022
|
Dinesh V Ph D Patel President and CEO |
SELL
Bona fide gift
|
Direct |
3,000
-0.51%
|
-
|
|
May 04
2022
|
Dinesh V Ph D Patel President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,742
+2.62%
|
$62,968
$4.21 P/Share
|
|
May 03
2022
|
William D. Waddill Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+50.0%
|
$96,000
$8.59 P/Share
|
|
Apr 26
2022
|
Dinesh V Ph D Patel President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+5.01%
|
$120,000
$4.21 P/Share
|
|
Apr 26
2022
|
Suneel Gupta Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+25.39%
|
$280,000
$7.38 P/Share
|
|
Apr 18
2022
|
Asif Ali Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+50.0%
|
-
|
|
Apr 14
2022
|
Dinesh V Ph D Patel President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,087
+5.96%
|
$34,087
$1.89 P/Share
|
|
Feb 28
2022
|
David Y Liu Chief R&D Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,119
-3.09%
|
$50,856
$24.28 P/Share
|
|
Feb 28
2022
|
Dinesh V Ph D Patel President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,648
-0.91%
|
$111,552
$24.28 P/Share
|
|
Feb 28
2022
|
Suneel Gupta Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
649
-0.84%
|
$15,576
$24.28 P/Share
|
|
Feb 15
2022
|
Dinesh V Ph D Patel President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+5.79%
|
-
|
|
Feb 15
2022
|
Suneel Gupta Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+13.86%
|
-
|
|
Feb 15
2022
|
David Y Liu Chief R&D Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+12.71%
|
-
|
|
Feb 15
2022
|
Donald A. Kalkofen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+28.82%
|
-
|
|
Dec 21
2021
|
Dinesh V Ph D Patel President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-3.05%
|
$480,000
$32.14 P/Share
|
|
Sep 21
2021
|
Dinesh V Ph D Patel President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+7.52%
|
$160,000
$4.21 P/Share
|
|
Aug 17
2021
|
David Y Liu Chief R&D Strategy Officer |
SELL
Open market or private sale
|
Direct |
14,779
-20.24%
|
$694,613
$47.56 P/Share
|
|
Aug 17
2021
|
David Y Liu Chief R&D Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.04%
|
$0
$0.87 P/Share
|
|
Feb 26
2021
|
Suneel Gupta Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+15.79%
|
-
|
|
Feb 26
2021
|
Donald A. Kalkofen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+41.93%
|
-
|
|
Feb 26
2021
|
David Y Liu Chief R&D Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+13.81%
|
-
|
|
Feb 26
2021
|
Dinesh V Ph D Patel President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+5.25%
|
-
|
|
Feb 26
2021
|
Samuel R Saks Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+46.15%
|
-
|
|
Feb 11
2021
|
Sarah B. Noonberg Director |
SELL
Open market or private sale
|
Direct |
3,700
-100.0%
|
$92,500
$25.09 P/Share
|
|
Feb 11
2021
|
Sarah B. Noonberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,700
+50.0%
|
$22,200
$6.98 P/Share
|
|
Feb 10
2021
|
Sarah B. Noonberg Director |
SELL
Open market or private sale
|
Direct |
4,700
-95.74%
|
$117,500
$25.73 P/Share
|
|
Feb 10
2021
|
Sarah B. Noonberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+50.0%
|
$28,200
$6.98 P/Share
|
|
Jan 19
2021
|
Dinesh V Ph D Patel President and CEO |
SELL
Open market or private sale
|
Direct |
24,846
-5.51%
|
$596,304
$24.6 P/Share
|
|
Jan 19
2021
|
Dinesh V Ph D Patel President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,000
+2.8%
|
$52,000
$4.21 P/Share
|
|
May 17
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
38,968
-1.81%
|
$233,808
$6.09 P/Share
|
|
May 16
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
29,441
-1.35%
|
$176,646
$6.46 P/Share
|
|
May 15
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
57,715
-2.57%
|
$346,290
$6.48 P/Share
|
|
May 14
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
77,591
-3.34%
|
$465,546
$6.37 P/Share
|
|
Mar 23
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
59,950
-2.52%
|
$1,199,000
$20.71 P/Share
|
|
Mar 22
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,759
-0.2%
|
$95,180
$20.62 P/Share
|
|
Mar 21
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
17,699
-0.74%
|
$353,980
$20.61 P/Share
|
|
Mar 20
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
17,060
-0.71%
|
$341,200
$20.61 P/Share
|
|
Mar 19
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,439
-0.55%
|
$268,780
$20.57 P/Share
|
|
Mar 16
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,926
-0.28%
|
$138,520
$20.51 P/Share
|
|
Mar 15
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
11,751
-0.48%
|
$235,020
$20.64 P/Share
|
|
Mar 14
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
200
-0.01%
|
$4,000
$20.77 P/Share
|
|
Mar 13
2018
|
Canaan X L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,204
-0.05%
|
$24,080
$20.84 P/Share
|
|
Aug 16
2016
|
Johnson & Johnson > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
583,333
+19.24%
|
$6,999,996
$12.0 P/Share
|
|
Aug 16
2016
|
Johnson & Johnson > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,865,850
+41.27%
|
-
|